Metropolitan Life Insurance Co NY trimmed its place in shares of Quest Diagnostics Incorporated (NYSE:DGX – Get Rating) by 47.9% throughout the first quarter, based on the corporate in its most up-to-date submitting with the Securities and Exchange Commission. The institutional investor owned 7,229 shares of the medical analysis firm’s inventory after promoting 6,658 shares throughout the interval. Metropolitan Life Insurance Co NY’s holdings in Quest Diagnostics had been value $989,000 as of its most up-to-date SEC submitting.
Quite a few different giant traders additionally lately modified their holdings of DGX. Mystic Asset Management Inc. bought a brand new place in shares of Quest Diagnostics throughout the 4th quarter valued at about $25,000. Sandy Cove Advisors LLC bought a brand new place in shares of Quest Diagnostics throughout the 1st quarter valued at about $28,000. Wagner Wealth Management LLC bought a brand new place in shares of Quest Diagnostics throughout the 4th quarter valued at about $35,000. Comprehensive Financial Consultants Institutional Inc. bought a brand new place in shares of Quest Diagnostics throughout the 4th quarter valued at about $38,000. Finally, NuWave Investment Management LLC bought a brand new place in shares of Quest Diagnostics throughout the 1st quarter valued at about $40,000. 88.87% of the inventory is owned by hedge funds and different institutional traders.
Quest Diagnostics Price Performance
Shares of DGX inventory opened at $125.13 on Monday. The agency has a market cap of $14.59 billion, a P/E ratio of 10.41 and a beta of 1.00. Quest Diagnostics Incorporated has a fifty-two week low of $124.28 and a fifty-two week excessive of $174.16. The business’s 50 day shifting common value is $135.17 and its 200-day shifting common value is $136.03. The firm has a debt-to-equity ratio of 0.62, a fast ratio of 1.42 and a present ratio of 1.54.
Quest Diagnostics (NYSE:DGX – Get Rating) final issued its quarterly earnings information on Thursday, July twenty first. The medical analysis firm reported $2.36 earnings per share for the quarter, topping analysts’ consensus estimates of $2.26 by $0.10. The agency had income of $2.45 billion for the quarter, in comparison with analyst estimates of $2.34 billion. Quest Diagnostics had a return on fairness of 24.62% and a internet margin of 14.02%. The business’s quarterly income was down 3.8% in comparison with the identical quarter final yr. During the identical interval final yr, the corporate earned $3.18 EPS. On common, equities analysis analysts anticipate that Quest Diagnostics Incorporated will publish 9.69 earnings per share for the present yr.
Quest Diagnostics Dividend Announcement
The agency additionally lately disclosed a quarterly dividend, which might be paid on Wednesday, October nineteenth. Stockholders of document on Tuesday, October 4th might be given a $0.66 dividend. The ex-dividend date of this dividend is Monday, October third. This represents a $2.64 dividend on an annualized foundation and a dividend yield of two.11%. Quest Diagnostics’s dividend payout ratio is at the moment 21.96%.
Insider Activity at Quest Diagnostics
In associated information, Director Timothy M. Ring bought 2,000 shares of Quest Diagnostics inventory in a transaction that occurred on Monday, August 1st. The inventory was bought at a mean value of $136.04, for a complete transaction of $272,080.00. Following the sale, the director now straight owns 23,933 shares in the corporate, valued at $3,255,845.32. The transaction was disclosed in a submitting with the Securities & Exchange Commission, which is obtainable on the SEC web site. 1.70% of the inventory is at the moment owned by company insiders.
Analyst Upgrades and Downgrades
Quite a few equities analysts have commented on the corporate. InventoryNews.com raised Quest Diagnostics from a “hold” ranking to a “buy” ranking in a analysis word on Thursday, July seventh. Morgan Stanley reaffirmed an “equal weight” ranking and issued a $142.00 value goal on shares of Quest Diagnostics in a analysis word on Monday, August twenty second. Six analysts have rated the inventory with a maintain ranking and three have issued a purchase ranking to the inventory. According to information from MarketBeat, the corporate has a consensus ranking of “Hold” and a consensus goal value of $148.50.
About Quest Diagnostics
(Get Rating)
Quest Diagnostics Incorporated offers diagnostic testing, data, and companies in the United States and internationally. The firm develops and delivers diagnostic data companies, akin to routine testing, non-routine and superior medical testing, anatomic pathology testing, and different diagnostic data companies.
Read More
Want to see what different hedge funds are holding DGX? Visit HoldingsChannel.com to get the newest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Get Rating).
Receive News & Ratings for Quest Diagnostics Daily – Enter your e-mail deal with under to obtain a concise day by day abstract of the newest information and analysts’ rankings for Quest Diagnostics and associated corporations with MarketBeat.com’s FREE day by day e-mail publication.
